A phase Ib study of the Akt inhibitor GDC-0068 with docetaxel (D) or mFOLFOX-6 (F) in patients (pts) with advanced solid tumors

被引：0
|
作者：
Saura, Cristina
Jones, Suzanne
Mateo, Joaquin
Hollebecque, Antoine
Cleary, James M.
Perez, Desamparados Roda
Zhu, Jin
Musib, Luna C.
Patel, Premal H.
Cervantes-Ruiperez, Andres
Isakoff, Steven J.
Soria, Jean-Charles
Molife, L. Rhoda
Tabernero, Josep
Bendell, Johanna C.
机构：
[1] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Royal Marsden Hosp, Surrey, England
[4] Inst Canc Res, Surrey, England
[5] Inst Gustave Roussy, Villejuif, France
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
[7] Hosp Clin, Dept Med Oncol, Colorectal Unit, Dept Surg, Valencia, Spain
[8] Genentech Inc, San Francisco, CA 94080 USA
[9] Univ Valencia, Dept Hematol & Med Oncol, INCLIVA, Valencia, Spain
[10] Massachusetts Gen Hosp, Boston, MA 02114 USA
[11] Sarah Cannon Res Inst Tennessee Oncol PLLC, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3021
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I and pharmacologic study of the vascular disrupting agent ombrabulin (Ob) combined with docetaxel (D) in patients (pts) with advanced solid tumors.
    Tresca, P.
    Tosi, D.
    van Doorn, L.
    Fontaine, H.
    Gaast, A. V.
    Veyrat-Follet, C.
    Oprea, C.
    Dieras, V.
    Eskens, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors: a phase I dose-escalation and pharmacokinetic (PK) study
    Traynor, A.
    Sandler, A.
    Schiller, J. H.
    Ilagan, J.
    Harper, K.
    VerMeulen, W.
    Liu, G.
    Tye, L.
    Chao, R.
    Robert, F.
    EJC SUPPLEMENTS, 2007, 5 (04): : 110 - 110
  • [33] A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors.
    LoRusso, Patricia
    Shapiro, Geoffrey
    Pandya, Shuchi Sumant
    Kwak, Eunice Lee
    Jones, Cheryl
    Belvin, Marcia
    Musib, Luna C.
    de Crespigny, Alex
    McKenzie, Meghan
    Gates, Mary R.
    Chan, Iris Tan-Chi
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] Phase Ib study of the oral PI3Kδ inhibitor linperlisib in patients with advanced solid tumors
    Li, Jin
    Xue, Junli
    Liu, Tianshu
    Feng, Yi
    Xu, Nong
    Huang, Jianjin
    Yin, Yongmei
    Zhang, Jun
    Mou, Haibo
    Shentu, Jiangzhong
    Bao, Hanying
    Xu, Zusheng
    Xu, Zuhong
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, 30 (02) : 241 - 251
  • [35] A phase Ib study of the PI3Kδ inhibitor linperlisib in patients with advanced solid tumors.
    Li, Jin
    Xu, Nong
    Liu, Tianshu
    Huang, Jianjin
    Yin, Yongmei
    Mou, Haibo
    Zhang, Jun
    Wu, Lihua
    Liu, Zong Liang
    Bao, Hanying
    Xu, Zusheng
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. Abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study).
    De Bono, Johann S.
    De Giorgi, Ugo
    Massard, Christophe
    Bracarda, Sergio
    Kocak, Ivo
    Font, Albert
    Arija, Jose Angel Arranz
    Shih, Kent C.
    Radavoi, George Daniel
    Yu, Wei
    Chan, Wai Y.
    Huang, Jian
    Musib, Luna C.
    Gendreau, Steven
    Meng, Raymond D.
    Patel, Premal H.
    Maslyar, Daniel J.
    Jinga, Vlore
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors
    Couteau, C
    Risse, ML
    Ducreux, M
    Lefresne-Soulas, F
    Riva, A
    Lebecq, A
    Ruffié, P
    Rougier, P
    Lokiec, F
    Bruno, R
    Armand, JP
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (20) : 3545 - 3552
  • [38] Docetaxel and ifosfamide in patients with advanced solid tumors: Results of a phase I study
    Pronk, LC
    Schrijvers, D
    Schellens, JHM
    de Bruijn, EA
    Planting, AST
    Locci-Tonelli, D
    Groult, V
    Verweij, J
    van Oosterom, AT
    SEMINARS IN ONCOLOGY, 1998, 25 (01) : 23 - 28
  • [39] Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors
    Pronk, LC
    Schellens, JHM
    Planting, AST
    vandenBent, MJ
    Hilkens, PHE
    vanderBurg, MEL
    deBoerDennert, M
    Ma, J
    Blanc, C
    Harteveld, M
    Bruno, R
    Stoter, G
    Verweij, J
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) : 1071 - 1079
  • [40] A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors
    Witta, SE
    Gustafson, DL
    Pierson, AS
    Menter, A
    Holden, SN
    Basche, M
    Persky, M
    O'Bryant, CL
    Zeng, C
    Baron, A
    Long, ME
    Gibbs, A
    Kelly, K
    Bunn, PA
    Chan, DC
    Pallansch, P
    Eckhardt, SG
    CLINICAL CANCER RESEARCH, 2004, 10 (21) : 7229 - 7237
12345